Victory Capital Management Inc. Raises Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Victory Capital Management Inc. grew its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 602.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 173,083 shares of the biopharmaceutical company's stock after acquiring an additional 148,456 shares during the period. Victory Capital Management Inc. owned 0.09% of Esperion Therapeutics worth $381,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ESPR. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Esperion Therapeutics by 71.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company's stock worth $1,174,000 after buying an additional 295,378 shares during the period. Intech Investment Management LLC bought a new stake in Esperion Therapeutics in the third quarter valued at $94,000. BNP Paribas Financial Markets raised its holdings in shares of Esperion Therapeutics by 152.7% during the third quarter. BNP Paribas Financial Markets now owns 123,333 shares of the biopharmaceutical company's stock valued at $203,000 after purchasing an additional 74,522 shares during the period. MetLife Investment Management LLC boosted its position in shares of Esperion Therapeutics by 47.1% during the 3rd quarter. MetLife Investment Management LLC now owns 71,050 shares of the biopharmaceutical company's stock worth $117,000 after purchasing an additional 22,734 shares in the last quarter. Finally, Wasatch Advisors LP grew its stake in shares of Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock valued at $38,521,000 after buying an additional 6,483,070 shares during the period. 47.39% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

ESPR has been the topic of several recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald began coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, March 20th. Finally, JMP Securities reissued a "market outperform" rating and set a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $6.75.

Esperion Therapeutics Trading Down 3.0 %

Shares of ESPR stock traded down $0.05 during trading on Wednesday, reaching $1.63. 3,615,344 shares of the company's stock traded hands, compared to its average volume of 5,842,032. Esperion Therapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $3.94. The company has a market capitalization of $322.49 million, a P/E ratio of -2.55 and a beta of 1.04. The firm's 50-day moving average is $1.81 and its 200 day moving average is $2.07.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.